Press Releases & News Articles

June, 2025

Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle HealthRead More »

June, 2025

Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With JuvenaRead More »

June, 2025

Eli Lilly works out $650M Juvena pact to find muscle-boosting drugsRead More »

May, 2025

Juvena Kicks Off First Human Trial of Muscle Regeneration TherapyRead More »

April, 2025

Our CEO, Hanadie Yousef, discussed Juvena’s growing and advancing pipeline of tissue restorative biologics for myopathies and obesity with Miranda Schmalfuhs from Pharmaceutical ExecutiveRead More »

March, 2025

Healthspan Capital highlights Juvena Therapeutics in its LongBio Report comprehensively profiling the leading companies in longevity biotechnologyRead More »

October, 2024

CEO Dr. Hanadie Yousef was nominated to Founders Forum’s 100 Women Founders to Watch,  which shines a light on 100 of the most exceptional women founders blazing a trail in the tech industry across UK & Europe, the United States, and Southeast AsiaRead More »

June, 2024

Longevity Technology highlights Juvena and others from the Longevity Summer DublinRead More »

June, 2024

Juvena is selected by the World Economic Forum to join its 2024 global cohort of Technology Pioneers, awarded to the 100 most innovative tech startups applying new breakthroughs in AI to solve some of the biggest challenges of our time.Read More »

April, 2024

CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.Read More »

March, 2024

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Read More »

March, 2024

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit Read More »

March, 2024

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leadersRead More »

March, 2024

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wastingRead More »

January, 2024

Juvena gets FDA Orphan Drug nod for muscle regeneration therapyRead More »

January, 2024

Juvena’s JUV-161 named FDA orphan drug for DM1Read More »

January, 2024

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1Read More »

January, 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1Read More »

January, 2024

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”Read More »

January, 2024

CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.Read More »

November, 2023

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.Read More »

October, 2023

Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.Read More »

August, 2023

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare Read More »

June, 2023

The Juvena team made a big splash at the 5th Age-Related Disease Therapeutics Summit in San Francisco! CEO, Dr. Hanadie Yousef gave a well received talk on mapping secreted proteins to unmet medical needs, as well as moderating the session of impressive speakers focused on biomarkers for age-related and chronic diseases. Juvena’s VP of Data Science, Dr. Eddie Moler co-led a pre-conference workshop on exploring the promise of AI-Powered drug discovery for the progression of age-related therapies, while Computational Biologist, Dr. Rohit Jadhav presented a poster on Juvena’s proteomics platform for mining the secretomes of stem cells. Read More »

May, 2023

Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makersRead More »

May, 2023

Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human healthRead More »

March, 2023

CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service.  Learn more here where she is quoted.Read More »

January, 2023

Biocom highlights backgrounds of Catalyst Award winners including CEO Hanadie YousefRead More »

January, 2023

As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!Read More »

January, 2023

BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteinsRead More »

January, 2023

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business DevelopmentRead More »

January, 2023

National Institute of Aging showcases Juvena TherapeuticsRead More »

December, 2022

Longevity Technology Spotlights the Early Beginnings and Future Vision of Juvena TherapeuticsRead More »

November, 2022

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of AgingRead More »

November, 2022

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related DiseasesRead More »

October, 2022

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.Read More »

February, 2022

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1Read More »

November, 2021

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)Read More »

February, 2020

Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020Read More »

January, 2020

Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity StartupsRead More »

October, 2019

Dr. Hanadie Yousef’s Entrepreneurship Recognized by Spark at StanfordRead More »

May, 2019

CEO Hanadie Yousef’s Most Recent Publication in Nature MedicineRead More »

March, 2019

Medium Blog Parameter Mentions Juvena TherapeuticsRead More »

March, 2019

Juvena Therapeutics Mentioned in ForbesRead More »

July, 2018

Juvena Therapeutics Mentioned in Middle Market GrowthRead More »

January, 2017

Antibody Can Protect Brains From the Ageing Effects of Old BloodRead More »

July, 2016

Hanadie Yousef, Cofounder and CEO, in Scope by Stanford MedicineRead More »

May, 2016

The Bloody Battle Against AgingRead More »

June, 2015

Featured in Vice: Engineering the End of AgingRead More »

May, 2015

CEO Highlighted in the Daily CalifornianRead More »

juvena-logo-wht

Navigation

Contact

640 Galveston Drive
Redwood City, CA 94063
Get Directions »
650.223.5879
info@juvenatherapeutics.com

Stay in touch

Subscribe to our newsletter

By entering your email you agree to our Privacy Policy

© 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy